SCHEMBL23219042

SCHEMBL23219042

CCOC(=O)Cc1ccccc1OCc1coc2ccc(-c3cc(F)cc(CNC(=O)OC(C)(C)C)c3)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.36
POLB P06746 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
GRM2 Q14416 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CFD P00746 4/20 0.34
MAPT P10636 3/20 0.34
BCHE P06276 2/20 0.33
CNR2 P34972 2/20 0.33
PSMB5 P28074 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
F11 P03951 3/20 0.33
TPSB2 P20231 1/20 0.33
HDAC1 Q13547 1/20 0.33
KLKB1 P03952 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852916 1.00 TP53 (0.36) TP53POLBNPSR1MEN1HPGD
SCHEMBL23218162 0.88 GRM2 (0.36) TP53POLBNPSR1MEN1HPGD
SCHEMBL29852557 0.88 GRM2 (0.36) TP53POLBNPSR1MEN1HPGD
SCHEMBL29852677 0.83 TP53 (0.36) TP53L3MBTL1CFDMAPTBCHE
SCHEMBL23218237 0.83 TP53 (0.36) TP53L3MBTL1CFDMAPTBCHE
SCHEMBL23218268 0.80 BRD4 (0.35) TP53MEN1KMT2AL3MBTL1CFD
SCHEMBL29853071 0.80 BRD4 (0.35) TP53MEN1KMT2AL3MBTL1CFD
SCHEMBL23218400 0.80 TP53 (0.42) TP53POLBMEN1KMT2AL3MBTL1
SCHEMBL29852595 0.80 TP53 (0.42) TP53POLBMEN1KMT2AL3MBTL1
SCHEMBL23218473 0.80 TP53 (0.35) TP53HPGDCFDMAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TP53 3891/4885POLB 3530/4885NPSR1 2875/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TP53 3580/4885POLB 2655/4885NPSR1 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.